San Francisco, California
London, United Kingdom
The Food and Drug Administration (FDA) is announcing a public meeting to obtain stakeholder input on the design and conduct of the postmarketing requirements (PMRs) for the class-wide extended-release/long-acting (ER/LA) opioid analgesic drug products to further assess the serious risks of misuse, abuse, hyperalgesia, addiction, overdose, and death associated with their long-term use.
The public meeting will be held on May 19 and 20, 2014, from 8 a.m. to 5 p.m on FDA's White Oak Campus. For more information, visit www.fda.gov/Drugs/NewsEvents/ucm384489.htm.